Synapse - Works

Results (3633)

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save

Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies

Meeting Abstract

Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term outcomes with single-agent BRAF-inhibitor therapy in Erdheim-Chester disease

Meeting Abstract

Goyal, G.; Reiner, A.; Bossert, D.; Sigler, A.; Buthorn, J.; Lacouture, M.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; more...
Blood (2023)

Fulltext@MSK | Save

A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial

Meeting Abstract

Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
Blood (2023)

Fulltext@MSK | Save

Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: Pilot analysis of circulating tumor DNA for patient eligibility confirmation and post-treatment response

Meeting Abstract

Imber, B.; Ravichandran, V.; Rao, P.; Casanova, H.; Friend, J.; Simpson, J.; Pike, L.; Zinovoy, M.; Mitchell, R.; Chacko, C.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability

Meeting Abstract

Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
Blood (2023)

Fulltext@MSK | Save

A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma

Meeting Abstract

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
Blood (2023)

Fulltext@MSK | Save

Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Primary endpoint results from the BLISSPHALL study

Meeting Abstract

Geyer, M. B.; Mascarenhas, J.; Smith, M.; Pascual, S.; Shah, A.; Silvestrone, M. R.; Czaplinska, T.; Johnson, K.; Thompson, M. C.; Park, J. H.
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save

Acupuncture vs massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial

Journal Article

Epstein, A. S.; Liou, K. T.; Romero, S. A. D.; Baser, R. E.; Wong, G.; Xiao, H.; Mo, Z. L.; Walker, D.; MacLeod, J.; Li, Q.; more...
JAMA Network Open (2023)

Fulltext@MSK | Save